To include your compound in the COVID-19 Resource Center, submit it here.

Cytori's Habeo Cell Therapy misses in Phase III scleroderma trial

Cytori Therapeutics Inc. (NASDAQ:CYTX) reported top-line data from the Phase III STAR trial in 88 patients with hand dysfunction due to scleroderma showing that Habeo Cell Therapy

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE